Osborne Clarke has advised the sellers of NanoSight Ltd, leaders in nanoparticle characterization on its sale to Malvern Instruments Ltd, the subsidiary of Spectris plc (LSE: SXS).

NanoSight Ltd is a scientific instrument manufacturer and world leaders in the design and development of particle size measurement instrumentation to the pharmaceutical, chemical and academic sectors world-wide.

NanoSight Ltd is also a Sunday Times 2013 Tech Track 100 company as one of Britain's fastest-growing private technology companies.

The Osborne Clarke team was led by Janita Good (Head of Life Sciences) and Thomas Colmer (Associate Director) assisted by Mark Braude (Senior Associate, Tax) and Sue El Hachmi (Senior Associate, Incentives).

John Knowles, Chairman of NanoSight Ltd comments:

"We found the Osborne Clarke team to be very proactive and ready to get the deal done.  They were not pedantic in their approach and project managed the overall process rather than concentrating on unnecessary detail.  Their advice on the various legal aspects of the deal was also sound and contributed to a very successful outcome."

Bob Carr, Founder and Chief Technical Director of NanoSight added:

"Osborne Clarke gave great advice and demonstrated their ability to explain technicalities simply and clearly.  We had full confidence in the OC team which was backed up by some very impressive negotiating skills.  It was a pleasure to work with them and an excellent outcome."

Jeremy Warren, Founder and CEO of NanoSight Ltd said:

"Osborne Clarke added much horsepower to our ability to reach the deal we sought.  Their people at all levels have worked with us as a cohesive team and this sale has been a collaborative team transaction”.

Janita Good commented:

“This is the 10th transaction that the Osborne Clarke Life Sciences and Healthcare team has advised on this year.  Our team is going from strength to strength.  We are always excited to work with entrepreneurial businesses with ground-breaking technologies."